In September, HHS awarded more than $103 million to 61 recipients—state, local and tribal government agencies and not-for-profit organizations—for interventions that address chronic-disease management, tobacco cessation, preventive services, healthy eating and other community wellness topics.
The CDC says it plans to focus on a subset of 30 of the 35 awardees that received implementation grants under the program. According to a notice in the Federal Register, the agency seeks to perform a cost-benefit analysis of these organizations' planned interventions, labor costs and other expenditures—a process it says will shed light on the best uses of limited resources.
Pending approval from the Office of Management and Budget, data collection for the 5-year project is set to begin in July 2012.
Read the notice at: http://tinyurl.com/83dth55
Source: Modern Healthcare
The Centers for Disease Control and Prevention (CDC) has proposed a project that would collect and analyze cost data from participants in the Community Transformation Grant program as part of an effort to predict chronic disease outcomes and their financial impacts.
OIG Report Seeks Better Oversight, Records for FDA’s Accelerated Approvals
February 3rd 2025Amid the uproar over the firing of 18 inspectors general, a report offering a coda to the aducanumab approval episode has been overlooked. It shows the need for reforms of the FDA's accelerated approval process.
Read More
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
January 23rd 2025On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Listen
New AGA Guidelines Recommend Risk-Based Prophylaxis for Hepatitis B Reactivation Monitoring
February 1st 2025The American Gastroenterology Association (AGA) updated its clinical practice guidelines for managing hepatitis B reactivation (HBVr) in at-risk individuals, recommending antiviral prophylaxis for high- and moderate-risk patients.
Read More